Form 4: enGene Holdings Inc. CEO Acquires 850,000 Stock Options
SEC Form 4 Filing
Ronald Harold Wilfred Cooper, CEO & President of enGene Holdings Inc., acquired 850,000 stock options on January 29, 2025, according to a Form 4 filing.
Summary
- Ronald Harold Wilfred Cooper, the CEO & President of enGene Holdings Inc., was granted 850,000 stock options on January 29, 2025.
- The exercise price of these options is $7.39.
- The options vest monthly in substantially equal amounts over 48 months, contingent upon Cooper's continued service.
- The options expire on January 29, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO to increase shareholder value.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of earliest transaction: Grant of 850,000 stock options. |
| 01/29/2035 | Expiration date of the stock options. |
| 01/31/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.